Neurotransmitters, the small molecule chemical messenger responsible for nervous system regulation and cancontrol joy, fear, depression, insomnia, craving for carbohydrates, drugs, and alcohols. Variation in neurotransmitterlevels is a characteristic manifestation of several neurological diseases. Accurate diagnosis of thesediseases caused due to an imbalance in neurotransmitter level followed by impaired transmission of signalsbetween neurons and other body parts remains a great challenge for the clinicians. Recent evidences reveal,artificial single-stranded nucleotides called ‘aptamer’ are widely used as biosensors, antibody substitutes,diagnostic agents, and for targeted therapy. These aptamers are superior candidate both for early detection anddiagnosis of many neurological disorders caused due to suboptimal level of neurotransmitters. Presently, noninvasiveneurotransmitter detection by aptamer has been found to be an easy, fast, and cost-effective choice. Inaddition, increased specificity, stability, affinity, and reproducibility of aptamers, high throughput screening ofaptamer-based sensing platforms have been observed. Moreover, clinical applicability of aptamer has alsoproved to be efficacious, though still at a preliminary stage. Herein, we review salient features of aptamerbasedsensing technology used for neurotransmitter detection particularly their chemical modifications,selection, assay development, immobilization, therapeutic efficiency, and stability for early diagnosis of diseasescaused due to neurotransmitter imbalance.
Volume 46, 2020
Continuous Article Publishing mode
Click here for Editorial Note on CAP Mode